Poison Control Data Show Ketamine Exposures Doubled 2019-2023 as Off-Label Use and Campus Availability Rise

The September 2026 civil suit filed by a former Cornell student alleges seven fraternity members pressured her to ingest ketamine before a group assault at a party. Ketamine produces rapid dissociation, amnesia, and impaired coordination lasting under an hour for primary effects, with residual judgment deficits persisting longer. Standard hospital urine screens miss the drug and its analogs, allowing covert administration in drinks or vaped products. Alcohol co-ingestion amplifies respiratory and cardiovascular risks. The plaintiff described social pressure rather than surreptitious dosing, a pattern toxicologists report is increasing on campuses where the drug is both prescribed off-label and diverted.

National Poison Data System analysis documented a doubling of ketamine exposure calls between 2019 and 2023, the highest annual totals recorded. The 2019 FDA approval of esketamine nasal spray for treatment-resistant depression expanded legitimate supply chains while basement-synthesized analogs entered street markets. Emergency physicians note that many cases involve voluntary use followed by impaired consent rather than classic drink spiking. Detection limitations and variable state reporting mean the true incidence on college campuses remains unknown.

Medical use expansion has simultaneously increased diversion and normalized the drug among students seeking rapid mood effects. Unlike earlier club-drug eras, current ketamine analogs evade routine toxicology and interact dangerously with alcohol and other substances common at parties. University health services lack validated screening protocols or real-time surveillance tied to sexual assault reports. Regulatory tracking of off-label prescribing remains fragmented across states.

Next steps require expanded poison center coding for novel analogs, pilot programs for point-of-care ketamine testing at student health centers, and longitudinal cohort studies linking prescribing volume to campus exposure rates. Without these, trends will continue undetected until case clusters prompt reactive policy.